查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030254

骨質疏鬆症藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按給藥途徑、藥物類型、地區和競爭格局分類，2021-2031年

Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Drug Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球骨質疏鬆症治療市場預計將從 2025 年的 143.3 億美元成長到 2031 年的 183.8 億美元，複合年成長率為 4.24%。

這些藥物旨在阻止骨骼劣化、增加骨骼密度並降低骨質疏鬆症患者的骨折風險。該領域的發展主要受人口老化、全球骨質疏鬆症發病率上升、診斷技術不斷進步以及骨骼健康意識宣傳活動日益普及等因素的推動。根據國際骨質疏鬆症基金會2025年10月報告，高達80%的骨質疏鬆性骨折患者未能得到針對病因的診斷或治療，顯示醫療介入方面存在巨大的機會。

市場概覽
預測期 2027-2031
市場規模：2025年 143.3億美元
市場規模：2031年 183.8億美元
複合年成長率：2026-2031年 4.24%
成長最快的細分市場 口服
最大的市場 北美洲

儘管骨質疏鬆症市場潛力巨大，但仍面臨一項重大挑戰：患者往往難以堅持長期治療方案。由於骨質疏鬆症通常沒有明顯症狀，因此這一問題更加突出。此外，尖端治療方法的高昂費用以及某些藥物的副作用風險也持續阻礙市場滲透。

市場促進因素

全球骨質疏鬆症及其相關骨折發生率的不斷上升，是推動骨質疏鬆症治療產業發展的主要動力。這種廣泛存在的疾病會顯著削弱骨骼，導致全球骨折病例激增，並增加了對治療的需求。根據國際骨質疏鬆症基金會2025年10月的數據，55歲以上人口每年將發生超過3700萬例脆性骨折，凸顯了龐大人群需要可靠的藥物治療來增強骨骼、降低骨折風險。如此高的發病率確保了對現有藥物和創新藥物的持續需求。

同時，全球老年人口的成長在加速市場發展方面發揮著至關重要的作用，因為老年人本身就更容易患上這種骨骼疾病。隨著全球平均壽命的延長，老年人口不斷成長，進一步擴大了高風險族群的範圍。世界衛生組織（世衛組織）在2025年2月預測，全球60歲及以上人口將從2023年的11億增加到2030年的14億，這將顯著擴大此類治療方法的消費群。這種人口結構的變化給醫療保健網路帶來了巨大的負擔，2025年發布的《應對骨折》報告預測，脆性骨折將為全球醫療保健系統帶來4000億美元的經濟負擔。

市場挑戰

全球骨質疏鬆症治療產業發展面臨的主要障礙之一是患者難以堅持長期治療方案。由於骨質疏鬆症通常沒有明顯症狀，導致患者忽視持續治療的需求或未能意識到處方藥物的即時療效，加劇了這個問題。結果，許多患者過早停藥，直接影響了治療效果。

治療不足將降低這些藥物的整體使用和長期需求，進而對市場擴張產生負面影響。 2025年8月，國際骨質疏鬆症基金會指出，約有20-30%的患者從未開始接受建議的口服雙磷酸鹽治療，而開始治療的患者中約有40%會在第一年內停止治療。如此高的停藥率會導致健康狀況惡化和骨折風險增加，最終阻礙市場擴張，因為這些藥物未能充分利用以阻止疾病進展或降低長期骨折率。

市場趨勢

全球骨質疏鬆症治療市場正經歷顯著的變革，這主要得益於生物製藥和合成代謝促效劑的廣泛應用，凸顯了人們對更強效、更精準的醫療干預手段的偏好。與傳統的抗骨吸收藥物不同，這些新型治療方法採用獨特的作用機制，例如主動促進新骨組織的形成。這項醫學進步使醫生能夠為重度骨質疏鬆症患者或對傳統療法無效的患者提供更佳的治療選擇，從而改善患者健康狀況並降低骨折風險。安進公司2026年2月發布的財報顯示，其骨形成藥物EVENITY（romosozumab-aqqg）在2025年的銷售額成長了34%，這充分體現了這些創新治療方法日益成長的市場接受度和商業性成功。

同時，生物相似藥的興起正透過提供價格更親民的替代生物製藥，顯著改變產業格局。此舉不僅改善了病患的用藥可及性，尤其是在醫療預算有限的地區，同時也加劇了製藥公司之間的競爭。生物相似藥的引入通常能夠降低成本，減輕患者的經濟負擔，使更多患者能夠獲得治療，並提高患者對長期治療方案的依從性。鑑於治療骨質疏鬆症常用生物製藥的替代療法顯著增加，歐洲藥品管理局於2025年核准了23Denosumab生物相似藥上市。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球骨質疏鬆症藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（口服、注射、其他）
    • 藥物類型（副甲狀腺素療法、雙磷酸鹽類藥物、抑鈣素、選擇性雌激素受體調節、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美骨質疏鬆症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲骨質疏鬆症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區骨質疏鬆症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲骨質疏鬆症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲骨質疏鬆症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球骨質疏鬆症藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5081

The Global market for osteoporosis medications is expected to expand from USD 14.33 billion in 2025 to USD 18.38 billion by 2031, reflecting a compound annual growth rate of 4.24%. These pharmaceuticals are designed to halt bone degradation, increase bone mineral density, and lower fracture risks for patients with the condition. Growth in this sector is largely fueled by a rising elderly demographic, a higher global incidence of osteoporosis, ongoing diagnostic improvements, and growing education around bone health. A substantial opportunity for medical intervention exists, as the International Osteoporosis Foundation reported in October 2025 that as many as 80% of individuals experiencing osteoporotic fractures were neither diagnosed nor treated for the root cause.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 14.33 Billion
Market Size 2031USD 18.38 Billion
CAGR 2026-20314.24%
Fastest Growing SegmentOral
Largest MarketNorth America

Despite this potential, the market faces significant hurdles related to patients failing to adhere to prolonged treatment regimens, a problem worsened because osteoporosis typically presents no visible symptoms. Additionally, the high expenses linked to cutting-edge therapies and the risk of adverse side effects from specific drugs continue to impede wider market adoption.

Market Driver

The increasing worldwide incidence of osteoporosis and its associated fractures acts as a major catalyst for the growth of the osteoporosis drug industry. This widespread condition severely weakens bones, causing a surge in fractures across the globe and driving up the need for medical treatments. Data from the International Osteoporosis Foundation in October 2025 indicated that individuals over the age of 55 experience more than 37 million fragility fractures annually, highlighting the massive group of patients who need reliable pharmaceutical care to strengthen their bones and lower fracture risks. This high frequency guarantees an ongoing demand for both established and innovative medications.

At the same time, the expanding global elderly population plays a crucial role in accelerating market advancement, given that seniors face a naturally higher vulnerability to this bone disease. With life expectancies lengthening globally, the older demographic is growing, creating a broader segment of individuals at risk. The World Health Organization projected in February 2025 that the global population of those aged 60 and above will climb from 1.1 billion in 2023 to 1.4 billion by 2030, substantially widening the consumer base for these treatments. This demographic transformation heavily strains healthcare networks, with Capture the Fracture reporting in 2025 that fragility fractures placed a $400 billion financial burden on global healthcare systems.

Market Challenge

A major obstacle restricting the growth of the worldwide osteoporosis medication industry is the difficulty patients have in sticking to extended treatment plans. This issue is frequently worsened by the fact that osteoporosis lacks obvious symptoms, causing individuals to overlook the continuous need for care or fail to notice any immediate positive effects from their prescriptions. As a result, a large number of patients stop taking their medications too soon, which directly compromises the success of their prescribed medical treatments.

Inadequate commitment to therapy negatively impacts market expansion by lowering the overall usage and long-term need for these drugs. In August 2025, the International Osteoporosis Foundation noted that roughly 20 to 30 percent of patients fail to begin their recommended oral bisphosphonate regimens altogether, while roughly 40 percent of those who start will quit within the initial year. This high level of discontinuation results in poorer health outcomes and a heightened likelihood of fractures, ultimately capping the market's reach since the medications are not adequately employed to halt disease advancement or lower long-term fracture rates.

Market Trends

The worldwide market for osteoporosis treatments is being heavily shaped by a noticeable transition toward sophisticated biologics and anabolic drugs, highlighting a preference for stronger, more precise medical interventions. Unlike standard antiresorptive medications, these modern options utilize unique methods of action, such as actively encouraging the generation of new bone tissue. This medical progression equips doctors with superior choices for individuals suffering from severe osteoporosis or those unresponsive to older treatments, paving the way for enhanced health results and a lower likelihood of broken bones. Demonstrating the rising acceptance and commercial success of these innovative options, Amgen's financial report from February 2026 revealed that sales for its anabolic drug EVENITY (romosozumab-aqqg) surged by 34% throughout 2025.

At the same time, the rising presence of biosimilars is significantly altering the industry landscape by providing budget-friendly substitutes for prominent biologic drugs. This development improves patient accessibility, especially in areas with limited healthcare funding, while sparking fiercer rivalry among pharmaceutical companies. The introduction of biosimilars generally drives down costs, which helps broaden the pool of patients receiving care and promotes better compliance with lengthy treatment schedules by easing economic pressures. Highlighting this major increase in accessible alternatives for a popular osteoporosis biologic, the European Medicines Agency authorized 23 denosumab biosimilars in 2025.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

Report Scope

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Route of Administration

  • Oral
  • Injectables
  • Others

Osteoporosis Drugs Market, By Drug Type

  • Parathyroid Hormone Therapy
  • Bisphosphonates
  • Calcitonin
  • Selective Estrogen Receptor Modulators
  • Others

Osteoporosis Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations:

Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteoporosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Injectables, Others)
    • 5.2.2. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Osteoporosis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Osteoporosis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Osteoporosis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Type

7. Europe Osteoporosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Osteoporosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Osteoporosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Osteoporosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Osteoporosis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Osteoporosis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Osteoporosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Osteoporosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Osteoporosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Osteoporosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Osteoporosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Osteoporosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Osteoporosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Osteoporosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Osteoporosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Osteoporosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Type

10. South America Osteoporosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Osteoporosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Osteoporosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Osteoporosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Osteoporosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. GlaxoSmithKline plc.
  • 15.6. Novartis International AG
  • 15.7. Merck & Co. Inc.
  • 15.8. Amgen Inc.
  • 15.9. Radius Health Inc.
  • 15.10. Actavis PLC

16. Strategic Recommendations

17. About Us & Disclaimer